BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.48
-0.02 (-0.24%)
At close: Mar 6, 2026, 4:00 PM EST
8.60
+0.12 (1.42%)
After-hours: Mar 6, 2026, 7:37 PM EST
BioCryst Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 874.84 | 450.71 | 331.41 | 270.83 | 157.17 | Upgrade
|
| Revenue Growth (YoY) | 94.10% | 36.00% | 22.37% | 72.31% | 782.38% | Upgrade
|
| Cost of Revenue | 180.93 | 185.71 | 216.47 | 259.89 | 216.07 | Upgrade
|
| Gross Profit | 693.91 | 265.01 | 114.94 | 10.94 | -58.9 | Upgrade
|
| Selling, General & Admin | 346.61 | 266.29 | 213.72 | 159.37 | 118.82 | Upgrade
|
| Operating Expenses | 346.61 | 266.29 | 213.72 | 159.37 | 118.82 | Upgrade
|
| Operating Income | 347.3 | -1.28 | -98.78 | -148.44 | -177.72 | Upgrade
|
| Interest Expense | -78.87 | -98.52 | -108.24 | -99.09 | -59.29 | Upgrade
|
| Interest & Investment Income | 10.67 | 14.75 | 15.78 | 5.13 | 0.06 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.15 | -0.64 | -1.04 | -1.98 | -0.7 | Upgrade
|
| Other Non Operating Income (Expenses) | 12.09 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 291.04 | -85.69 | -192.28 | -244.38 | -237.65 | Upgrade
|
| Merger & Restructuring Charges | -6.31 | -1.26 | -3.38 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0 | Upgrade
|
| Asset Writedown | - | - | -1.55 | - | - | Upgrade
|
| Other Unusual Items | -17.33 | - | -29.02 | - | 55.84 | Upgrade
|
| Pretax Income | 267.39 | -86.95 | -226.23 | -244.38 | -181.81 | Upgrade
|
| Income Tax Expense | 3.53 | 1.93 | 0.31 | 2.73 | 2.25 | Upgrade
|
| Net Income | 263.86 | -88.88 | -226.54 | -247.12 | -184.06 | Upgrade
|
| Net Income to Common | 263.86 | -88.88 | -226.54 | -247.12 | -184.06 | Upgrade
|
| Shares Outstanding (Basic) | 210 | 207 | 192 | 186 | 179 | Upgrade
|
| Shares Outstanding (Diluted) | 219 | 207 | 192 | 186 | 179 | Upgrade
|
| Shares Change (YoY) | 5.75% | 7.54% | 3.38% | 3.79% | 7.08% | Upgrade
|
| EPS (Basic) | 1.26 | -0.43 | -1.18 | -1.33 | -1.03 | Upgrade
|
| EPS (Diluted) | 1.21 | -0.43 | -1.18 | -1.33 | -1.03 | Upgrade
|
| Free Cash Flow | 344.9 | -53.14 | -97.31 | -163.2 | -144.54 | Upgrade
|
| Free Cash Flow Per Share | 1.58 | -0.26 | -0.51 | -0.88 | -0.81 | Upgrade
|
| Gross Margin | 79.32% | 58.80% | 34.68% | 4.04% | -37.48% | Upgrade
|
| Operating Margin | 39.70% | -0.28% | -29.81% | -54.81% | -113.07% | Upgrade
|
| Profit Margin | 30.16% | -19.72% | -68.36% | -91.25% | -117.11% | Upgrade
|
| Free Cash Flow Margin | 39.42% | -11.79% | -29.36% | -60.26% | -91.97% | Upgrade
|
| EBITDA | 348.69 | -0.03 | -97.13 | -146.18 | -176.83 | Upgrade
|
| EBITDA Margin | 39.86% | -0.01% | -29.31% | -53.98% | -112.51% | Upgrade
|
| D&A For EBITDA | 1.39 | 1.25 | 1.66 | 2.25 | 0.89 | Upgrade
|
| EBIT | 347.3 | -1.28 | -98.78 | -148.44 | -177.72 | Upgrade
|
| EBIT Margin | 39.70% | -0.28% | -29.81% | -54.81% | -113.07% | Upgrade
|
| Effective Tax Rate | 1.32% | - | - | - | - | Upgrade
|
| Revenue as Reported | 874.84 | 450.71 | 331.41 | - | - | Upgrade
|
| Advertising Expenses | 13.82 | 13.57 | 14.4 | 14.89 | 5.71 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.